Symbols / RXRX $3.38 -0.29%
RXRX Chart
About
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.79B |
| Enterprise Value | 1.12B | Income | -644.76M | Sales | 74.68M |
| Book/sh | 2.14 | Cash/sh | 1.41 | Dividend Yield | — |
| Payout | 0.00% | Employees | 600 | IPO | — |
| P/E | — | Forward P/E | -3.97 | PEG | — |
| P/S | 23.91 | P/B | 1.58 | P/C | — |
| EV/EBITDA | -1.99 | EV/Sales | 15.03 | Quick Ratio | 5.20 |
| Current Ratio | 5.50 | Debt/Eq | 6.89 | LT Debt/Eq | — |
| EPS (ttm) | -1.44 | EPS next Y | -0.85 | EPS Growth | — |
| Revenue Growth | 6.82% | Earnings | 2026-05-05 | ROA | -27.72% |
| ROE | -59.54% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -3.29% | Profit Margin | 0.00% | Shs Outstand | 521.95M |
| Shs Float | 510.12M | Short Float | 33.76% | Short Ratio | 7.76 |
| Short Interest | — | 52W High | 7.18 | 52W Low | 2.98 |
| Beta | 0.96 | Avg Volume | 20.57M | Volume | 4.50M |
| Target Price | $6.71 | Recom | Buy | Prev Close | $3.39 |
| Price | $3.38 | Change | -0.29% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.71
Mean price target
2. Current target
$3.42
Latest analyst target
3. DCF / Fair value
$-7.19
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.42
Low
$3.00
High
$11.00
Mean
$6.71
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-26 | main | B of A Securities | Neutral → Neutral | $6 |
| 2026-02-26 | reit | Needham | Buy → Buy | $8 |
| 2025-12-17 | up | JP Morgan | Neutral → Overweight | $11 |
| 2025-09-11 | reit | Needham | Buy → Buy | $8 |
| 2025-07-08 | reit | Needham | Buy → Buy | $8 |
| 2025-06-16 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $5 |
| 2025-05-06 | main | Needham | Buy → Buy | $8 |
| 2025-04-10 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $8 |
| 2025-04-08 | reit | Needham | Buy → Buy | $11 |
| 2025-02-28 | main | Leerink Partners | Market Perform → Market Perform | $6 |
| 2025-02-06 | reit | Needham | Buy → Buy | $11 |
| 2025-01-08 | main | Keybanc | Overweight → Overweight | $10 |
| 2024-12-11 | reit | Needham | Buy → Buy | $11 |
| 2024-11-20 | reit | Needham | Buy → Buy | $11 |
| 2024-11-07 | reit | Needham | Buy → Buy | $11 |
| 2024-09-04 | main | Needham | Buy → Buy | $11 |
| 2024-09-03 | main | Jefferies | Hold → Hold | $6 |
| 2024-09-03 | main | Leerink Partners | Market Perform → Market Perform | $8 |
| 2024-08-09 | main | Needham | Buy → Buy | $16 |
| 2024-07-11 | main | Keybanc | Overweight → Overweight | $12 |
- RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up - Yahoo Finance Wed, 25 Feb 2026 08
- A Look At Recursion Pharmaceuticals (RXRX) Valuation After Q4 Beat And AI Clinical Progress - simplywall.st hu, 12 Mar 2026 06
- AI-powered biotech Recursion posts first clinical proof, $753.9M cash - Stock Titan Wed, 25 Feb 2026 08
- Recursion Pharmaceuticals (NASDAQ:RXRX) CEO Sells $94,798.30 in Stock - MarketBeat Wed, 11 Mar 2026 22
- RXRX Stock Surges on JPMorgan Upgrade, Trial Data Gains - Forbes hu, 18 Dec 2025 08
- Recursion Pharmaceuticals Stock (RXRX) Opinions on Upcoming Earnings Report - Quiver Quantitative Sun, 22 Feb 2026 08
- The Bull Case For Recursion Pharmaceuticals (RXRX) Could Change Following Nvidia’s Exit And ARK’s Big Buy-In - Yahoo Finance Mon, 23 Feb 2026 08
- Nvidia Dumped Recursion Pharmaceuticals Stock. Should You? - Yahoo Finance hu, 19 Feb 2026 08
- Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? - Yahoo Finance Wed, 24 Dec 2025 08
- Jim Cramer on Recursion Pharmaceuticals: “It’s a Let Down, Big Let Down” - Yahoo Finance Fri, 13 Mar 2026 15
- Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance Fri, 23 Jan 2026 08
- Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Recent 1‑Year Share Slump Accurately - Yahoo Finance ue, 10 Mar 2026 12
- Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance ue, 10 Feb 2026 08
- Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance hu, 08 Jan 2026 08
- Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance Fri, 20 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 20000 | — | — | Stock Gift at price 0.00 per share. | GIBSON CHRISTOPHER | Director | — | 2026-03-09 00:00:00 | D |
| 1 | 28298 | 94660.0 | — | Sale at price 3.35 per share. | KHAN NAJAT | Chief Executive Officer | — | 2026-03-09 00:00:00 | D |
| 2 | 20000 | nan | — | — | GIBSON CHRISTOPHER | Director | — | 2026-03-09 00:00:00 | D |
| 3 | 170000 | 588200.0 | — | Sale at price 3.46 per share. | BORGESON BLAKE CHARLES | Director | — | 2026-03-03 00:00:00 | D |
| 4 | 40000 | 138400.0 | — | Sale at price 3.46 per share. | GIBSON CHRISTOPHER | Director | — | 2026-02-19 00:00:00 | D |
| 5 | 40000 | nan | — | — | GIBSON CHRISTOPHER | Director | — | 2026-02-19 00:00:00 | D |
| 6 | 13426 | 41352.0 | — | Sale at price 3.08 per share. | TAYLOR BEN R | Chief Financial Officer | — | 2026-02-18 00:00:00 | D |
| 7 | 30346 | — | — | Stock Award(Grant) at price 0.00 per share. | GIBSON CHRISTOPHER | Director | — | 2026-02-06 00:00:00 | D |
| 8 | 526318 | — | — | Stock Award(Grant) at price 0.00 per share. | DAVID HALLETT | Officer | — | 2026-02-06 00:00:00 | D |
| 9 | 1703892 | — | — | Stock Award(Grant) at price 0.00 per share. | KHAN NAJAT | Chief Executive Officer | — | 2026-02-06 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.01 | 0.00 |
| NormalizedEBITDA | -559.38M | -426.72M | -307.63M | -227.66M |
| TotalUnusualItems | 0.00 | 0.00 | -827.00K | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | 0.00 | -827.00K | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -644.76M | -463.66M | -328.07M | -239.48M |
| ReconciledDepreciation | 83.70M | 36.49M | 24.40M | 11.76M |
| ReconciledCostOfRevenue | 70.95M | 45.24M | 42.59M | 48.27M |
| EBITDA | -559.38M | -426.72M | -307.63M | -227.66M |
| EBIT | -643.09M | -463.22M | -332.03M | -239.42M |
| NetInterestIncome | 20.98M | 14.19M | 19.02M | 6.20M |
| InterestExpense | 1.81M | 1.57M | 97.00K | 55.00K |
| InterestIncome | 22.79M | 15.76M | 19.12M | 6.25M |
| NormalizedIncome | -644.76M | -463.66M | -328.07M | -239.48M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -644.76M | -463.66M | -328.07M | -239.48M |
| TotalExpenses | 722.39M | 537.49M | 393.94M | 285.41M |
| TotalOperatingIncomeAsReported | -648.13M | -479.00M | -350.06M | -245.73M |
| DilutedAverageShares | 447.45M | 274.21M | 207.85M | 175.54M |
| BasicAverageShares | 447.45M | 274.21M | 207.85M | 175.54M |
| DilutedEPS | -1.44 | -1.69 | -1.58 | -1.36 |
| BasicEPS | -1.44 | -1.69 | -1.58 | -1.36 |
| DilutedNIAvailtoComStockholders | -644.76M | -463.66M | -328.07M | -239.48M |
| NetIncomeCommonStockholders | -644.76M | -463.66M | -328.07M | -239.48M |
| NetIncome | -644.76M | -463.66M | -328.07M | -239.48M |
| NetIncomeIncludingNoncontrollingInterests | -644.76M | -463.66M | -328.07M | -239.48M |
| NetIncomeContinuousOperations | -644.76M | -463.66M | -328.07M | -239.48M |
| TaxProvision | -136.00K | -1.13M | -4.06M | 0.00 |
| PretaxIncome | -644.89M | -464.79M | -332.13M | -239.48M |
| OtherIncomeExpense | -17.74M | 30.00K | -1.09M | 52.00K |
| OtherNonOperatingIncomeExpenses | -17.74M | 30.00K | -1.09M | 52.00K |
| SpecialIncomeCharges | 0.00 | 0.00 | -827.00K | |
| OtherSpecialCharges | 827.00K | |||
| NetNonOperatingInterestIncomeExpense | 20.98M | 14.19M | 19.02M | 6.20M |
| InterestExpenseNonOperating | 1.81M | 1.57M | 97.00K | 55.00K |
| InterestIncomeNonOperating | 22.79M | 15.76M | 19.12M | 6.25M |
| OperatingIncome | -648.13M | -479.00M | -350.06M | -245.73M |
| OperatingExpense | 651.43M | 492.25M | 351.35M | 237.13M |
| OtherOperatingExpenses | -425.00K | -351.00K | -699.00K | -162.00K |
| ResearchAndDevelopment | 475.27M | 314.42M | 241.23M | 155.70M |
| SellingGeneralAndAdministration | 176.59M | 178.18M | 110.82M | 81.60M |
| GeneralAndAdministrativeExpense | 176.59M | 178.18M | 110.82M | 81.60M |
| OtherGandA | 176.59M | 178.18M | 110.82M | 81.60M |
| GrossProfit | 3.30M | 13.25M | 1.29M | -8.59M |
| CostOfRevenue | 70.95M | 45.24M | 42.59M | 48.27M |
| TotalRevenue | 74.26M | 58.49M | 43.88M | 39.68M |
| OperatingRevenue | 74.26M | 58.49M | 43.88M | 39.68M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 528.18M | 396.80M | 234.27M | 191.02M |
| ShareIssued | 528.18M | 396.80M | 234.27M | 191.02M |
| TotalDebt | 77.97M | 108.49M | 50.67M | 51.01M |
| TangibleBookValue | 658.80M | 550.05M | 374.94M | 483.70M |
| InvestedCapital | 1.15B | 1.06B | 464.58M | 486.44M |
| WorkingCapital | 665.14M | 526.80M | 344.97M | 469.55M |
| NetTangibleAssets | 658.80M | 550.05M | 374.94M | 483.70M |
| CapitalLeaseObligations | 59.31M | 81.05M | 49.53M | 50.37M |
| CommonStockEquity | 1.13B | 1.03B | 463.44M | 485.81M |
| TotalCapitalization | 1.14B | 1.05B | 464.54M | 486.34M |
| TotalEquityGrossMinorityInterest | 1.13B | 1.03B | 463.44M | 485.81M |
| StockholdersEquity | 1.13B | 1.03B | 463.44M | 485.81M |
| GainsLossesNotAffectingRetainedEarnings | 36.72M | -7.64M | 0.00 | 0.00 |
| OtherEquityAdjustments | 36.72M | -7.64M | -126.00K | |
| RetainedEarnings | -2.08B | -1.43B | -967.62M | -639.56M |
| AdditionalPaidInCapital | 3.17B | 2.47B | 1.43B | 1.13B |
| CapitalStock | 5.00K | 4.00K | 2.00K | 2.00K |
| CommonStock | 5.00K | 4.00K | 2.00K | 2.00K |
| TotalLiabilitiesNetMinorityInterest | 343.26M | 413.82M | 190.26M | 215.48M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 195.56M | 226.34M | 97.09M | 115.22M |
| OtherNonCurrentLiabilities | 2.08M | 4.73M | ||
| NonCurrentDeferredLiabilities | 137.27M | 135.34M | 52.58M | 70.26M |
| NonCurrentDeferredRevenue | 114.01M | 118.77M | 51.24M | 70.26M |
| NonCurrentDeferredTaxesLiabilities | 23.25M | 16.57M | 1.34M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 56.21M | 86.27M | 44.52M | 44.96M |
| LongTermCapitalLeaseObligation | 46.65M | 67.25M | 43.41M | 44.42M |
| LongTermDebt | 9.56M | 19.02M | 1.10M | 536.00K |
| CurrentLiabilities | 147.71M | 187.47M | 93.17M | 100.27M |
| CurrentDeferredLiabilities | 37.60M | 61.77M | 36.43M | 56.73M |
| CurrentDeferredRevenue | 37.60M | 61.77M | 36.43M | 56.73M |
| CurrentDebtAndCapitalLeaseObligation | 21.75M | 22.22M | 6.16M | 6.05M |
| CurrentCapitalLeaseObligation | 12.66M | 13.79M | 6.12M | 5.95M |
| CurrentDebt | 9.09M | 8.43M | 41.00K | 97.00K |
| OtherCurrentBorrowings | 9.09M | 8.43M | 41.00K | 97.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 31.77M | 50.85M | 22.89M | 20.43M |
| PayablesAndAccruedExpenses | 56.58M | 52.63M | 27.70M | 17.06M |
| CurrentAccruedExpenses | 38.46M | 31.02M | 23.75M | 12.47M |
| Payables | 18.12M | 21.61M | 3.95M | 4.59M |
| AccountsPayable | 18.12M | 21.61M | 3.95M | 4.59M |
| TotalAssets | 1.47B | 1.45B | 653.70M | 701.29M |
| TotalNonCurrentAssets | 661.28M | 734.33M | 215.56M | 131.47M |
| OtherNonCurrentAssets | 18.79M | 14.45M | 6.89M | 7.92M |
| NonCurrentDeferredAssets | 957.00K | 1.93M | 0.00 | |
| NonCurrentDeferredTaxesAssets | 957.00K | 1.93M | 0.00 | |
| GoodwillAndOtherIntangibleAssets | 472.06M | 484.73M | 88.50M | 2.11M |
| OtherIntangibleAssets | 309.90M | 335.86M | 36.44M | 1.31M |
| Goodwill | 162.16M | 148.87M | 52.06M | 801.00K |
| NetPPE | 169.48M | 233.21M | 120.17M | 121.45M |
| AccumulatedDepreciation | -89.21M | -62.67M | -44.87M | -30.11M |
| GrossPPE | 258.69M | 295.88M | 165.04M | 151.56M |
| Leases | 70.78M | 72.73M | 45.93M | 41.87M |
| ConstructionInProgress | 511.00K | 2.71M | 3.23M | 8.75M |
| OtherProperties | 158.71M | 193.08M | 93.76M | 80.78M |
| MachineryFurnitureEquipment | 28.69M | 27.36M | 22.13M | 20.16M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 812.85M | 714.27M | 438.14M | 569.81M |
| OtherCurrentAssets | 28.57M | 38.11M | 40.25M | 15.87M |
| RestrictedCash | 4.59M | 3.04M | 3.23M | 1.28M |
| PrepaidAssets | 11.74M | 29.60M | ||
| Receivables | 24.65M | 49.17M | 3.09M | 2.75M |
| OtherReceivables | 24.65M | 49.17M | 3.09M | 2.75M |
| AccountsReceivable | 0.00 | 34.00K | ||
| CashCashEquivalentsAndShortTermInvestments | 743.29M | 594.35M | 391.56M | 549.91M |
| OtherShortTermInvestments | 0.00 | 231.45M | ||
| CashAndCashEquivalents | 743.29M | 594.35M | 391.56M | 549.91M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -380.44M | -376.22M | -300.33M | -120.88M |
| RepaymentOfDebt | -8.43M | -4.44M | -766.00K | -90.00K |
| IssuanceOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 528.86M | 300.42M | 128.09M | 143.71M |
| CapitalExpenditure | -8.63M | -17.05M | -12.55M | -37.36M |
| InterestPaidSupplementalData | 96.00K | 55.00K | 680.00K | |
| EndCashPosition | 753.92M | 603.02M | 401.43M | 559.11M |
| BeginningCashPosition | 603.02M | 401.43M | 559.11M | 295.35M |
| EffectOfExchangeRateChanges | 18.04M | -3.41M | 188.00K | -307.00K |
| ChangesInCash | 132.85M | 205.00M | -157.88M | 264.07M |
| FinancingCashFlow | 521.53M | 304.12M | 140.13M | 154.34M |
| CashFlowFromContinuingFinancingActivities | 521.53M | 304.12M | 140.13M | 154.34M |
| NetOtherFinancingCharges | -3.00M | |||
| ProceedsFromStockOptionExercised | 4.09M | 8.14M | 12.81M | 10.72M |
| NetPreferredStockIssuance | 0.00 | 0.00 | ||
| PreferredStockIssuance | 0.00 | 0.00 | ||
| NetCommonStockIssuance | 528.86M | 300.42M | 128.09M | 143.71M |
| CommonStockIssuance | 528.86M | 300.42M | 128.09M | 143.71M |
| NetIssuancePaymentsOfDebt | -8.43M | -4.44M | -766.00K | -90.00K |
| NetLongTermDebtIssuance | -8.43M | -4.44M | -766.00K | -90.00K |
| LongTermDebtPayments | -8.43M | -4.44M | -766.00K | -90.00K |
| LongTermDebtIssuance | 0.00 | 0.00 | ||
| InvestingCashFlow | -16.87M | 260.06M | -10.23M | 193.25M |
| CashFlowFromContinuingInvestingActivities | -16.87M | 260.06M | -10.23M | 193.25M |
| NetInvestmentPurchaseAndSale | -3.81M | 0.00 | 480.00K | 230.61M |
| SaleOfInvestment | 0.00 | 0.00 | 480.00K | 230.61M |
| PurchaseOfInvestment | -3.81M | 0.00 | 0.00 | 0.00 |
| NetBusinessPurchaseAndSale | -4.44M | 277.10M | 1.84M | 0.00 |
| SaleOfBusiness | 0.00 | 277.10M | 1.84M | 0.00 |
| PurchaseOfBusiness | -4.44M | 0.00 | 0.00 | 0.00 |
| NetIntangiblesPurchaseAndSale | -2.16M | -3.35M | -597.00K | -300.00K |
| PurchaseOfIntangibles | -2.16M | -3.35M | -597.00K | -300.00K |
| NetPPEPurchaseAndSale | -6.47M | -13.70M | -11.96M | -37.06M |
| PurchaseOfPPE | -6.47M | -13.70M | -11.96M | -37.06M |
| OperatingCashFlow | -371.81M | -359.17M | -287.78M | -83.52M |
| CashFlowFromContinuingOperatingActivities | -371.81M | -359.17M | -287.78M | -83.52M |
| ChangeInWorkingCapital | 13.69M | -46.76M | -44.26M | 104.92M |
| ChangeInOtherWorkingCapital | -36.77M | -28.04M | -41.08M | 110.32M |
| ChangeInOtherCurrentLiabilities | -19.99M | -15.58M | -9.86M | -7.11M |
| ChangeInPayablesAndAccruedExpense | -12.35M | 11.69M | 8.44M | 1.71M |
| ChangeInAccruedExpense | -9.73M | 5.25M | 9.42M | -54.00K |
| ChangeInPayable | -2.62M | 6.43M | -987.00K | 1.77M |
| ChangeInAccountPayable | -2.62M | 6.43M | -987.00K | 1.77M |
| ChangeInPrepaidAssets | 49.86M | -8.76M | 6.00M | |
| ChangeInReceivables | 32.94M | -6.07M | -7.76M | -2.00K |
| ChangesInAccountReceivables | 114.00K | |||
| OtherNonCashItems | 53.88M | 32.95M | 5.45M | 8.56M |
| StockBasedCompensation | 111.22M | 81.69M | 53.50M | 27.91M |
| AssetImpairmentCharge | 5.96M | 108.00K | 1.19M | 2.81M |
| DepreciationAmortizationDepletion | 83.70M | 36.49M | 24.40M | 11.76M |
| DepreciationAndAmortization | 83.70M | 36.49M | 24.40M | 11.76M |
| OperatingGainsLosses | 4.50M | 827.00K | ||
| GainLossOnSaleOfBusiness | 4.50M | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperations | -644.76M | -463.66M | -328.07M | -239.48M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for RXRX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|